Comparative Pharmacology
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus TICLOPIDINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPROBAMATE AND ASPIRIN versus TICLOPIDINE HYDROCHLORIDE.
MEPROBAMATE AND ASPIRIN vs TICLOPIDINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meprobamate is a carbamate derivative that acts as a CNS depressant, potentiating GABA-A receptor activity and inhibiting polysynaptic spinal reflexes. Aspirin irreversibly acetylates cyclooxygenase-1 and -2 (COX-1/2), inhibiting prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Ticlopidine is a thienopyridine inhibitor of platelet aggregation. It irreversibly inhibits the P2Y12 receptor on platelets, blocking ADP-mediated platelet activation and aggregation.
Aspirin 325 mg and meprobamate 200 mg orally every 6 to 8 hours as needed for pain or anxiety. Maximum daily dose: aspirin 3.9 g, meprobamate 1.6 g.
250 mg orally twice daily
None Documented
None Documented
Aspirin: 15-20 minutes (parent drug), but salicylate half-life is dose-dependent: 2-3 hours for low doses, 15-30 hours for high doses. Meprobamate: 6-17 hours (mean 10 hours), prolonged in overdose or hepatic impairment.
The terminal elimination half-life is approximately 24-36 hours after single-dose administration, prolonging to 4-5 days after multiple dosing due to time-dependent pharmacokinetics. This necessitates a loading dose regimen (e.g., 250 mg twice daily) to achieve steady-state within 2-3 days.
Aspirin: Renal excretion of salicylates (75% as salicyluric acid, 10% as salicylic acid, 10% as phenolic glucuronide, 5% as acyl glucuronide). Meprobamate: Renal excretion (10-20% unchanged, 80-90% as hydroxylated metabolites) and biliary excretion (<5%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 60% of the dose, with 23% excreted in feces as metabolites. Less than 2% of the dose is excreted unchanged in urine.
Category D/X
Category A/B
NSAID / Antiplatelet
Antiplatelet